Praxis Precision Medicines, Inc. Common Stock
$308.99
-$3.91 (-1.25%)
$303.88Day Range$321.95
Key Statistics
Market Cap
$8.63B
Shares Outstanding
27.9M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 16, 2020
Round Lot
40
Locale
US
Trading Data
Day Open
$315.22
Day High
$321.95
Day Low
$303.88
Volume
545.8K
VWAP
$311.21
Prev Close
$312.90
Transactions
--
Acc. Volume
--
About Praxis Precision Medicines, Inc. Common Stock
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
PHARMACEUTICAL PREPARATIONSSIC 283410,998 employees99 HIGH STREET, 30TH FLOOR, BOSTON, MA, 02110617-300-8460IPO Oct 16, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001689548
- Composite FIGI
- BBG00W9LF2G5
- Share Class FIGI
- BBG00W9LF2H4
- Ticker Root
- PRAX
- SIC Code
- 2834
About Praxis Precision Medicines, Inc. Common Stock (PRAX) Stock
Praxis Precision Medicines, Inc. Common Stock (PRAX) closed the 2026-09-16 session at $308.99, down 1.25% versus the previous close (-3.91). The stock opened at $315.22 and traded between $303.88 and $321.95 during that session. Session trading volume was 546K shares. The volume-weighted average price (VWAP) is $311.21.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Praxis Precision Medicines, Inc. Common Stock has a market capitalization of $8.63 billion. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PRAX is listed on the XNAS exchange. The company employs approximately 10,998 people. Praxis Precision Medicines, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2020-10-16.
On this page you can find market PRAX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.